The routine use of once-daily, oral abrocitinib (Janus kinase 1 selective inhibitor)  dosed at 100 or 200 mg can be effective in improving the symptoms and health-related quality of life (QoL) in adolescent and adults suffering from moderate-to-severe atopic dermatitis (AD) as deciphered from a pooled analysis of 3 studies issued in American Journal of Clinical Dermatology.

Jonathan I. Silverberg et al. studied the effect of abrocitinib in AD patients in terms of patient-reported outcomes of specific signs and symptoms linked with the disease and QoL. The pooled data from one phase IIb and two phase III trials comprising of 942 individuals with atopic dermatitis were examined.

Itch (Night Time Itch Scale (NTIS)), overall severity, and multiple scales concerning the signs and symptoms were reported under the assessments of patient-reported outcomes. Anxiety, depression (Hospital Anxiety and Depression Scales (HADS)), fatigue, disease- and general health-linked QoL, and work and general efficiency among working patients via Work Productivity and Activity Impairment Questionnaire: Atopic Dermatitis (WPAI: AD) were also evaluated.

As found, there were improvements across all the patient-reported outcomes from week 2 to week 12 in patients in 200 mg, 100 mg, and placebo as shown in the following table 1:

The results of this analysis offered notable information on the efficacy of abrocitinib from the perception of patients and complement clinician-reported efficacy and safety outcomes, as concluded.